An announcement from Morphic Holding (MORF) is now available.
Morphic Holding, Inc. has launched an at-the-market offering program allowing for the sale of up to $350 million of its common stock through TD Securities (USA) LLC. This flexible financing strategy enables the company to sell shares at prevailing market prices, with TD Cowen receiving a commission of up to 3%. Morphic intends to use the proceeds for general corporate purposes, including research, clinical trials, and potential acquisitions. The move follows the company’s termination of a previous agreement with Jefferies LLC, under which it sold over $139 million in common stock.
See more insights into MORF stock on TipRanks’ Stock Analysis page.
